FDA gives companies leeway to go after misinformation, but not free reign
In a new revised draft guidance document, the FDA says it will allow life sciences companies to address misinformation about their products that is posted online. While the policy is similar in some respects to one first created by the FDA in 2014, the latest version is considerably more detailed regarding what it will – and won’t – allow companies to do.
The FDA is responsible for ensuring that medical products are adequately labeled in accordance with federal regulations, including the product’s “intended use” and relevant safety information.
Fill out the form to read the full article.
Required *